144 related articles for article (PubMed ID: 1809700)
1. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
Miljković B; Pokrajac M; Varagić V; Lević Z
Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
[TBL] [Abstract][Full Text] [Related]
2. Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers.
Kulkarni C; Vaz J; David J; Joseph T
Indian J Physiol Pharmacol; 1995 Apr; 39(2):122-6. PubMed ID: 7649598
[TBL] [Abstract][Full Text] [Related]
3. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
4. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
Fattore C; Messina S; Battino D; Croci D; Mamoli D; Perucca E
Epilepsy Res; 2006 Aug; 70(2-3):153-60. PubMed ID: 16730950
[TBL] [Abstract][Full Text] [Related]
5. Steady-state valproate pharmacokinetics during long term therapy.
Eadie MJ; Heazlewood V; McKauge L; Tyrer JH
Clin Exp Neurol; 1983; 19():183-91. PubMed ID: 6439443
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability of different valproic acid formulations.
Franke G; Diletti E; Hoffmann C; Zschiesche M; Scheuch E; Siegmund W
Int J Clin Pharmacol Ther; 1995 Dec; 33(12):653-7. PubMed ID: 8963482
[TBL] [Abstract][Full Text] [Related]
7. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.
Ragueneau-Majlessi I; Levy RH; Brodie M; Smith D; Shah J; Grundy JS
Clin Pharmacokinet; 2005; 44(5):517-23. PubMed ID: 15871637
[TBL] [Abstract][Full Text] [Related]
9. Single-dose model for predicting steady-state valproic acid serum concentrations in seizure patients.
Pugh CB; Garnett WR; Poynor WJ; Pellock JM
Clin Pharm; 1984; 3(6):643-9. PubMed ID: 6439455
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
[TBL] [Abstract][Full Text] [Related]
11. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid clearance in children with epilepsy.
Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I
J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
14. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats.
Yu HY; Shen YZ; Sugiyama Y; Hanano M
Drug Metab Dispos; 1990; 18(1):121-6. PubMed ID: 1970771
[TBL] [Abstract][Full Text] [Related]
15. Prediction of steady-state concentrations of valproic acid as determined from single plasma concentrations after the first dose.
May CA; Garnett WR
Clin Pharm; 1983; 2(2):143-7. PubMed ID: 6411412
[TBL] [Abstract][Full Text] [Related]
16. [Influence of age, body weight and dose on sodium valproate plasma concentrations in children with epilepsy].
Jiang Z; Zhang J; Liao HM; Tang JW; Peng QL
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):325-8. PubMed ID: 18554460
[TBL] [Abstract][Full Text] [Related]
17. Divalproex-ER pharmacokinetics in older children and adolescents.
Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
19. Sodium valproate: dose-plasma level relationships and interdose fluctuations.
Vajda FJ; Mihaly GW; Miles JL; Morris PM; Bladin PF
Clin Exp Neurol; 1978; 15():145-53. PubMed ID: 386306
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
